Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12331159 | 0.81 | CYP1A2 (0.52) | CYP1A2TDP1HTTPOLBALDH1A1 | |
| SCHEMBL303850 | 0.78 | TDP1 (0.54) | CYP1A2TDP1HTR1AMAPTALDH1A1 | |
| SCHEMBL12331158 | 0.77 | — | — | |
| SCHEMBL303849 | 0.76 | CYP1A2 (0.52) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL18823195 | 0.76 | CYP1A2 (0.52) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL15934198 | 0.76 | CYP1A2 (0.52) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL13015354 | 0.75 | ALDH1A1 (0.50) | HTTHSD11B1POLBLMNANPSR1 | |
| SCHEMBL6932584 | 0.74 | TDP1 (0.56) | CYP1A2TDP1HTR1AHTTHSD11B1 | |
| SCHEMBL9153460 | 0.74 | ALDH1A1 (0.62) | CYP1A2TDP1HTR1AHTTPOLB | |
| SCHEMBL847825 | 0.74 | ALDH1A1 (0.62) | CYP1A2TDP1HTR1AHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372528-A1 | GLYCOCONJUGATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-3612537-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-3919492-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020156453-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | 南京明德新药研发有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-20200115390-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| US-10188746-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| EP-2265588-B1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | NR0B2, HRH3, NR0B1 | CYP1A2 494/4885TDP1 3652/4885HTR1A 495/4885 |
| US-20230372528-A1 | GLYCOCONJUGATES | CD22, SIGLEC7, CD47 | CYP1A2 3641/4885TDP1 2308/4885HTR1A 3850/4885 |
| US-20200115390-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | NR0B2, HRH3, NR0B1 | CYP1A2 494/4885TDP1 3652/4885HTR1A 495/4885 |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | BCR, UGT2B17, BCL6B | CYP1A2 361/4885TDP1 3229/4885HTR1A 575/4885 |
| US-10188746-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD22, GABRA1, CCNB1 | CYP1A2 722/4885TDP1 2369/4885HTR1A 968/4885 |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD22, GABRA1, CCNB1 | CYP1A2 722/4885TDP1 2369/4885HTR1A 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.